Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 50Lymphoid 47Myeloid 24Plasma cell 13Sarcoma 7Gynecologic 7Dermatologic 7Thoracic 6Head & Neck 5Genitourinary 5Gastrointestinal 5Classical hematology 5Other solid neoplasm 4Breast 3Tumor-Agnostic 2Other neoplasm 2CNS 2Endocrine 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 18Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Biopsy 7Paclitaxel 6Nivolumab 6atezolizumab 5Cyclophosphamide 5Surveys and Questionnaires 4Standard of Care 4Practice Guidelines as Topic 4Oxaliplatin 4Ipilimumab 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3X-Rays 3Radiotherapy 3Radiosurgery 3Radiation 3Pemetrexed 3Leucovorin 3Irinotecan 3Interviews as Topic 3Fluorouracil 3Carboplatin 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × fludarabine × Tumor-Agnostic × Clear all
NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
7 enrolled 15 charts
Tumor-Agnostic

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

USWM, LLC (dba US WorldMeds)

Phase 2 Active not recruiting
87 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡